ClinConnect ClinConnect Logo
Search / Trial NCT05100342

Prospective Validation of a Points Score System Predicting 30-day Survival

Launched by INDIANA UNIVERSITY · Oct 18, 2021

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Palliative Radiation Radiation Therapy

ClinConnect Summary

This clinical trial is looking to test a new tool that helps predict how long patients with metastatic cancer might survive after they start palliative radiation therapy. Palliative therapy is aimed at relieving symptoms and improving quality of life rather than curing the cancer. The study will gather important information about each patient, like their lab results and medical history, to give them a survival score when they join the trial.

To be eligible for this study, participants need to be at least 18 years old and have a diagnosis of cancer that has spread. They should be referred to radiation oncology for palliative treatments, but it’s important to note that patients can still participate even if they decide not to receive radiation or if it's not recommended for them. Those who start but don't finish their radiation treatment can also take part. Throughout the trial, participants can expect follow-up visits, which can be done virtually or over the phone.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 at time of consent
  • 2. Ability to provide written informed consent
  • 3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy
  • 4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible
  • 5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible
  • Note: Patients who ultimately do not complete prescribed radiation will remain eligible
  • Exclusion Criteria:
  • 1. Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted)
  • 2. Patients who are receiving definitive/curative course of radiation therapy
  • 3. Patients who self-report as pregnant or nursing

About Indiana University

Indiana University, a leading research institution, is committed to advancing healthcare through innovative clinical trials and rigorous scientific inquiry. With a focus on improving patient outcomes, the university conducts a wide range of studies across various medical disciplines, leveraging its extensive resources and collaborative networks. Indiana University's dedication to ethical research practices and community engagement ensures that its clinical trials not only contribute to scientific knowledge but also prioritize participant safety and well-being. Through its commitment to excellence, Indiana University plays a pivotal role in shaping the future of medicine and enhancing public health.

Locations

Indianapolis, Indiana, United States

Indianapolis, Indiana, United States

Indianapolis, Indiana, United States

Carmel, Indiana, United States

Avon, Indiana, United States

Carmel, Indiana, United States

Patients applied

0 patients applied

Trial Officials

Naoyuki Saito, MD PhD

Principal Investigator

Indiana University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials